MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: General Electric Company
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Healthcare and World Courier Collaborate to Drive Commercialization of Cell and Gene Therapies - Collaborative effort specific to cell and gene therapy designed to support patients and increase access to advanced treatments - WorldCourier.com / GEHealthcare.com
GE Healthcare and World Courier Collaborate to Drive Commercialization of Cell and Gene Therapies

 

NewswireToday - /newswire/ - Chicago, IL, United States, 2019/05/31 - Collaborative effort specific to cell and gene therapy designed to support patients and increase access to advanced treatments - WorldCourier.com / GEHealthcare.com. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GE Healthcare and World Courier, a part of AmerisourceBergen, are combining their expertise in manufacturing and logistics to better patient access to cell and gene therapies. Together, they aim to create a seamless end-to-end supply chain that will enable the developers of these treatments to meet increasing global demand. This collaboration is designed to support the commercialization of advanced therapies.

By leveraging the manufacturing efficiencies of GE Healthcare’s FlexFactory™, a semi-automated, modular end-to-end manufacturing platform, and World Courier’s robust global logistics platform, drug manufacturers will be able to deliver life-altering therapies that have time- and temperature- critical conditions globally.

Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare, said: “As GE Healthcare works to advance the development of cell and gene therapies, it is critical that we offer our customers agile solutions that can help them meet global demand. By working with World Courier and leveraging their robust logistics platform and global infrastructure, we are providing a solution that will spur commercialization and access to next generation therapeutics.”

Sam Herbert, President, World Courier, said: “At World Courier, we are committed to moving medicine forward. We’ve developed a proprietary network and global footprint that meets the constantly evolving shipping requirements and complex therapeutics of today. Cell and gene manufacturers deserve a partner that treats patients and their life-changing therapies as well as they would, at every step. By collaborating with GE and their FlexFactory platform, we’re taking our commitment one step further and creating an economic and scalable supply chain that helps ensure the efficient and successful delivery of cell and gene therapies to global patients.”

With more than 900 regenerative medicine companies and more than 1,000 clinical trials underway worldwide in 2018, [1] the industry is growing at an exponential pace. Creating robust supply chains that can efficiently scale up and connect the right therapies to the right patient is key to enabling the commercialization of cell and gene therapies.

About GE Healthcare

GE Healthcare (gehealthcare.com) is the $19.8 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics, and monitoring through intelligent devices, data analytics, applications, and services. With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world.

About World Courier

World Courier (worldcourier.com) provides unparalleled specialty logistics services to drive the commercial success of our partners around the globe. For 50 years, we’ve delivered peace of mind through world-class supply chain programs, transportation services, storage of time- and temperature-sensitive products, and innovative, cutting-edge medicines including cell and gene therapies. Through our daily work and powered by our nearly 3,000 associates we are united in our responsibility to create healthier futures. With a presence in 50+ countries, World Courier is driven by a commitment to excellence, and provides customized solutions with global reach to increase access to care; making us the most trusted specialty logistics company in the world.

Media Contact: Francesca Gunning - AmerisourceBergen
P: +610 727 7433 / +215 603 9264
E: fgunning[.]amerisourcebergen.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GE Healthcare and World Courier Collaborate to Drive Commercialization of Cell and Gene Therapies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Colleen Connolly - GE Healthcare 
774-245-3893 colleen.Connolly[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)